4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc & Avi), Biotinylated [TMPY-05594]

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

サプライヤー: TargteMol
カタログNo.: TMPY-05594
製品名称: 4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc & Avi), Biotinylated
タンパク質名: 4-1BB/CD137/TNFRSF9
Species: Human
HOST: HEK293 Cells

Synonyms	CDw137, CD137, 4-1BB, tumor necrosis factor receptor superfamily, member 9, ILA
Characteristics	Measured by its binding ability in a functional ELISA.?Immobilized S4-Fc3L3-TNFSF9 at 10 μg/mL (100 μL/well) can bind TNFRSF9-Fc-Avi , the EC50 of TNFRSF9-Fc-Avi is15-40 ng/mL.
Endotoxin Level	< 1.0 EU/μg of the protein as determined by the LAL method.
Purity	94.60%
Description	4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 45.8 kDa and the accession number is Q07011.
Reference	Sica G,et al.(1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.,Wang Q,et al.(2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.,Melero I,et al.(2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.,Nam KO,et al.(2005)?The therapeutic potential of 4-1BB (CD137) in cancer.?Curr Cancer Drug Targets. 5(5): 357-63.,Thum E,et al.(2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
URL	https://www.targetmol.com/recombinant-protein/4_1bb_cd137_protein_human_recombinant_ecd_hfc_avi_tag_biotinylated

バイオ製品Bio Products